Overview

A Study to Investigate the Pharmacokinetics of RO7223280 in Critically Ill Participants With Bacterial Infections

Status:
Recruiting
Trial end date:
2023-12-26
Target enrollment:
Participant gender:
Summary
The main aim of the study is to investigate the plasma pharmacokinetics (PK) and safety of intravenous (IV) administration of a single dose of 600 mg RO7223280 in critically ill participants with bacterial infections.
Phase:
Phase 1
Details
Lead Sponsor:
Hoffmann-La Roche